# US Pleurisy Market > US Pleurisy Market Research Report By Type (Acute Pleurisy, Chronic Pleurisy, Recurrent Pleurisy), By Diagnosis Method (Physical Examination, Imaging Tests, Laboratory Tests), By Treatment Type (Medication, Surgical Procedures, Therapeutic Procedures) and By End User (Hospitals, Clinics, Home Care) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.45% - **2024:** $ 137.2 Million - **2025:** $ 147.42 Million - **2035:** $ 302.51 Million - **Key Players:** Pfizer Inc (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Roche Holding AG (CH), AstraZeneca PLC (GB), Merck & Co., Inc. (US), Johnson & Johnson (US), Gilead Sciences, Inc. (US) **Report ID:** MRFR/MED/18468-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-pleurisy-market-20015 --- ## Market Summary ## **US Pleurisy Market Overview** As per MRFR analysis, the US Pleurisy Market Size was estimated at 363.3 (USD Million) in 2023. The US Pleurisy Market Industry is expected to grow from 384.3(USD Million) in 2024 to 829.55 (USD Million) by 2035. The US Pleurisy Market CAGR (growth rate) is expected to be around 7.246% during the forecast period (2025 - 2035). ### **Key US Pleurisy Market Trends Highlighted** The US Pleurisy Market is witnessing significant trends shaped by various factors. One of the key market drivers is the rising incidence of respiratory diseases, which has increased the awareness surrounding pleurisy as a condition. As healthcare providers focus on improving diagnosis and treatment options for respiratory ailments, the demand for effective pleurisy therapies and diagnostic tools has seen a considerable rise. The aging population in the US also contributes to this trend, as older adults are more susceptible to pleuritic conditions. Opportunities to be explored include the development of innovative therapeutic solutions and diagnostics. Advances in medical technology, such as image-guided interventions and minimally invasive surgical procedures, present an avenue for healthcare companies to introduce new treatment options. Moreover, the increasing emphasis on personalized medicine offers a chance to tailor pleurisy treatments based on individual patient profiles, potentially leading to better outcomes and improved patient satisfaction. Recent trends demonstrate a shift towards comprehensive patient care that includes patient education and management programs. There is a growing focus on multidisciplinary approaches to treating pleurisy, with healthcare providers collaborating to create integrated care pathways. This trend aims to enhance patient understanding of their condition, foster better communication between patients and providers, and ultimately elevate the standards of care in the US. The regulatory environment is also evolving, with increased support for research and development in respiratory care from governmental agencies. This regulatory support not only encourages innovation but also enhances the overall quality of pleurisy treatment, thus reinforcing the importance of ongoing medical research in this area. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Pleurisy Market Drivers** ### **Rising Incidence of Respiratory Diseases** The increasing prevalence of respiratory diseases in the United States is a significant driver for the US [Pleurisy Market](../../../reports/pleurisy-market-1711) Industry. According to data from the Centers for Disease Control and Prevention (CDC), chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), affect over 30 million people in the US. With rising pollution levels and increased exposure to environmental allergens, the number of patients suffering from pleurisy conditions is also expected to rise, enhancing the demand for medical interventions and therapies. The projected growth in respiratory disease cases creates a pertinent market opportunity, prompting healthcare companies to develop focused treatment solutions. Consequently, pharmaceutical firms like Pfizer and GlaxoSmithKline are likely to invest in Research and Development for pleurisy-related treatments, given the projected increase in patients and their associated healthcare needs. ### **Advancements in Medical Technology** Technological advancements in diagnostic methods and treatment options are fueling growth in the US Pleurisy Market Industry. Innovations such as computerized tomography (CT) scans and ultrasound-guided pleural procedures have made diagnosing and managing pleurisy significantly more effective and precise. For instance, the American College of Chest Physicians highlights that enhanced imaging techniques have increased the accuracy of diagnosing pleural effusions. The introduction of minimally invasive procedures for fluid drainage and the growing adoption of telemedicine for patient management represent crucial trends. As technology continues to evolve, healthcare facilities in the US are likely to incorporate these advanced solutions, leading to improved patient outcomes and contributing to market growth. ### **Increasing Investment in Healthcare** The rising investment in healthcare infrastructure in the United States is a vital factor driving the US Pleurisy Market Industry. With policy shifts and increased funding directed towards healthcare facilities, particularly post-COVID-19, there is an expanded focus on improving patient care standards. The American Hospital Association reports that hospitals are expected to receive substantial federal aid and grants, which will enable them to purchase advanced medical technologies and hire specialized staff for managing conditions like pleurisy. This revitalization of healthcare infrastructure, coupled with an increase in health insurance coverage, is likely to encourage early diagnosis and treatment, which can enhance market prospects in the pleurisy segment. ## **US Pleurisy Market Segment Insights** ### **Pleurisy Market Type Insights** The US Pleurisy Market exhibits substantial diversity when it comes to its Type segmentation, consisting of Acute Pleurisy, Chronic Pleurisy, and Recurrent Pleurisy. Acute Pleurisy is often characterized by sudden onset and is frequently caused by infections, injury, or other related conditions, making it an essential focal point for healthcare providers, especially in emergency settings across the US. Chronic Pleurisy differs in that it persists for an extended timeframe, commonly resulting from underlying health issues like autoimmune diseases or persistent infections, thus presenting unique challenges for long-term management and treatment strategies. This segment demands a comprehensive approach, requiring both immediate and ongoing healthcare interventions to improve patient outcomes over time. Furthermore, the Recurrent Pleurisy category captures attention as it relates to patients experiencing multiple episodes, which may indicate more severe underlying health complications, thus necessitating additional diagnostic assessments and tailored treatment plans. The interplay between these types denotes significant implications on the overall US Pleurisy Market statistics, illustrating a complex and varied landscape of treatment needs, patient demographics, and healthcare resource allocation. The presence of these three types sheds light on the broader public health considerations and varying levels of clinical management required, presenting opportunities for innovation in therapeutic options, patient education, and awareness campaigns in the US. Market growth in this area is guided by an increase in the rates of infections and other underlying conditions, alongside an aging population that is more prone to respiratory diseases. Consequently, understanding the unique characteristics and demands associated with each type of Pleurisy not only informs clinical practice but also assists in strategic decision-making within the healthcare industry to better serve the evolving needs of patients across the United States. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Pleurisy Market Diagnosis Method Insights** The US Pleurisy Market focuses significantly on the Diagnosis Method segment, which is essential for accurate identification and treatment of this respiratory condition. This segment primarily encompasses Physical Examination, Imaging Tests, and Laboratory Tests, each playing a vital role in the diagnostic process. Physical Examination is often the first step, where healthcare professionals assess patient symptoms and respiratory function, aiding in immediate evaluations. Imaging Tests, such as X-rays and CT scans, are critical for visualizing pleural inflammation and distinguishing pleurisy from similar conditions, thus ensuring appropriate clinical decisions. Laboratory Tests, which include pleural fluid analysis and blood tests, are fundamental for confirming diagnoses and determining underlying causes. The increasing prevalence of respiratory diseases and the growing demand for precise diagnostic tools drive the importance of these methods within the US Pleurisy Market. Furthermore, advancements in imaging technologies and laboratory techniques continue to enhance diagnostic accuracy and efficiency, presenting opportunities for market growth. Overall, the robust approach to Diagnosis Method underlines its significance in managing pleurisy effectively, supporting better patient outcomes and recovery rates. ### **Pleurisy Market Treatment Type Insights** The Treatment Type segment of the US Pleurisy Market is critical in addressing the needs of patients suffering from this condition, which involves inflammation of the pleura surrounding the lungs. This segment can be divided into key areas such as Medication, Surgical Procedures, and Therapeutic Procedures. Medication plays a significant role as it often serves as the first line of treatment, focusing on pain relief and reducing inflammation. Surgical Procedures may be required in severe cases, showcasing their importance in managing complications or underlying conditions. Therapeutic Procedures are also vital as they help in fluid removal and alleviation of symptoms, which is crucial for patient recovery. As the US population ages and related respiratory issues become more prevalent, the demand for effective treatment options in the US Pleurisy Market is anticipated to rise. Furthermore, advancements in medical technologies and increasing awareness among healthcare providers contribute to the growth of this segment, presenting a significant opportunity for innovation and improvement in patient outcomes in this continuously evolving industry. ### **Pleurisy Market End User Insights** The End User segment of the US Pleurisy Market exhibits diverse applications that cater to various healthcare settings, including hospitals, clinics, and home care. Hospitals play a critical role in the treatment and management of pleurisy, often serving as the primary facility where acute cases are diagnosed and treated, as they are equipped with advanced technology and specialist healthcare providers. Clinics contribute significantly by offering outpatient services, enhancing access to care for less severe cases of pleurisy, allowing for timely intervention and management. The home care sector is gaining prominence, reflecting a shift towards patient-centered care wherein individuals prefer recovery in familiar environments; this approach improves comfort and potentially leads to better patient outcomes. With heightened awareness and a growing elderly population in the US, the demand across these End User segments is likely to increase, driven by several factors, including advancements in healthcare technologies and a focus on effective pain management solutions. This diversification within the End User segment not only enhances the overall accessibility of care related to pleurisy but also provides significant opportunities for growth within the US Pleurisy Market. Overall, the segmentation underscores the importance of tailored healthcare delivery across various platforms to address the unique needs of pleurisy patients effectively. ## **US Pleurisy Market Key Players and Competitive Insights** The US Pleurisy Market demonstrates a complex mix of competitive dynamics, shaped by various stakeholders including pharmaceutical companies, healthcare providers, and regulatory entities. The disease itself, characterized by inflammation of the pleura, has led to an increasing demand for effective therapeutic solutions. Key players in this market continuously innovate and strive to enhance their product portfolios while also focusing on research and development. Competition is not solely based on product efficacy but also on pricing strategies, distribution capabilities, and market accessibility. The involvement of regulatory agencies in approving medical treatments adds another layer of complexity, influencing the market’s competitive landscape. Therefore, the competitive insights into this market draw their significance from understanding how various companies navigate regulatory challenges, innovate therapeutics, and the ways they differentiate themselves from rivals. Bristol Myers Squibb holds a notable position in the US Pleurisy Market with a commitment to research that continually drives the development of specialized treatments aimed at alleviating symptoms associated with pleurisy. The company is noted for its robust portfolio that includes therapies which improve patient outcomes and their quality of life. Bristol Myers Squibb has established strong relationships with healthcare professionals, enhancing its market presence and credibility among stakeholders. Their strength also lies in extensive clinical trials which not only facilitate product approval but also garner trust among patients and providers seeking effective treatment options. With a solid foundation in immunology and oncology, their strategies emphasize innovative approaches to medical therapies relevant to pleurisy, enabling them to maintain a competitive edge. AstraZeneca is an influential player in the US Pleurisy Market, known for its active involvement in providing treatment options for respiratory diseases. The company’s product offerings, particularly focus on therapies aimed at managing inflammation linked with pleurisy, showcases its responsiveness to patient needs. AstraZeneca has built a commendable market presence through strategic partnerships and collaborations that enhance its research efforts in the pleurisy segment. Strengths of the company include a robust pipeline of products that leverage both small molecules and biologics, providing a comprehensive approach to treatment. Furthermore, AstraZeneca's commitment to accelerating innovation through mergers and acquisitions showcases its ambition to expand its capabilities in addressing pleurisy and related conditions effectively. This strategic direction not only strengthens their market offering but also reinforces their leadership role in the evolving landscape of treatments available for pleurisy in the United States. ### **Key Companies in the US Pleurisy Market Include** ## **US Pleurisy Market Industry Developments** In recent months, the US Pleurisy Market has seen substantial developments, especially with companies like Bristol Myers Squibb, AstraZeneca, and Merck making strides in treatment advancements. The market has been impacted by increased investment in Research and Development (R&D) focused on pleural diseases, with Eli Lilly and Novartis actively expanding their portfolios. Notably, in October 2023, Merck announced promising trial results for a new drug aimed at pleurisy, raising anticipation among stakeholders. In terms of mergers and acquisitions, there has been heightened interest in strategic partnerships, although no significant transactions have been reported recently among the key companies, including Regeneron Pharmaceuticals and Pfizer. The growth of the market valuation for companies like Roche and AbbVie has been substantial over the past two years, driven by an improved understanding of pleural diseases and enhanced healthcare policies that effectively support patient care. Traditional therapies are also witnessing improvements, supporting major industry players as they adapt their strategies to market demands. Additionally, the commitment from the FDA to expedite approvals for new therapeutics has contributed to a more dynamic marketplace for pleurisy treatments in the US. ## **US Pleurisy Market Segmentation Insights** ### **Pleurisy Market Type Outlook** ### **Pleurisy Market Diagnosis Method Outlook** ### **Pleurisy Market Treatment Type Outlook** ### **Pleurisy Market End User Outlook** ## Market Drivers ### Growing Geriatric Population The aging population in the US is a significant factor influencing the pleurisy market. As individuals age, they become more susceptible to respiratory diseases and related complications, including pleurisy. The US Census Bureau projects that by 2030, approximately 20% of the population will be aged 65 and older. This demographic shift is likely to result in a higher incidence of pleurisy, as older adults often experience weakened immune systems and chronic health conditions. Consequently, healthcare systems may need to allocate more resources to manage pleurisy cases, thereby driving demand for treatments and services within the pleurisy market. The implications of this trend could lead to increased healthcare expenditures and a focus on preventive care. ### Rising Healthcare Expenditure The upward trend in healthcare spending in the US is a crucial driver for the pleurisy market. With healthcare expenditures projected to reach $6 trillion by 2027, there is a growing emphasis on investing in effective treatments for respiratory conditions. This increase in funding allows for better research, development, and accessibility of pleurisy treatments. Furthermore, as insurance coverage expands and more patients seek care, the demand for pleurisy-related services is expected to rise. The financial commitment to healthcare may lead to innovations in treatment options and improved patient education, ultimately fostering growth in the pleurisy market. ### Enhanced Healthcare Infrastructure Improvements in healthcare infrastructure across the US are positively impacting the pleurisy market. The expansion of hospitals, clinics, and telehealth services has made it easier for patients to access care for respiratory conditions. According to the American Hospital Association, there has been a 5% increase in the number of hospitals equipped to handle respiratory illnesses in recent years. This enhanced infrastructure facilitates timely diagnosis and treatment of pleurisy, potentially reducing complications and hospital stays. As healthcare facilities continue to evolve and adapt to patient needs, the pleurisy market is likely to benefit from increased patient engagement and improved health outcomes. ### Advancements in Treatment Modalities Innovations in treatment options for pleurisy are driving the pleurisy market forward. The development of new anti-inflammatory medications and targeted therapies has improved patient outcomes and reduced recovery times. Recent studies indicate that the introduction of biologics and corticosteroids has led to a 30% improvement in symptom management for pleurisy patients. Furthermore, the rise of minimally invasive procedures for fluid drainage has enhanced the therapeutic landscape. As these advancements continue to emerge, they are expected to attract investment and research, thereby stimulating growth in the pleurisy market. The ongoing evolution of treatment modalities may also lead to increased awareness and diagnosis of pleurisy. ### Rising Incidence of Respiratory Diseases The increasing prevalence of respiratory diseases in the US is a notable driver for the pleurisy market. Conditions such as pneumonia, tuberculosis, and chronic obstructive pulmonary disease (COPD) contribute to a heightened incidence of pleurisy. According to the Centers for Disease Control and Prevention (CDC), respiratory diseases account for a significant portion of hospital admissions, with pneumonia alone leading to over 1 million hospitalizations annually. This trend suggests a growing patient population that may develop pleurisy as a complication, thereby expanding the market. The pleurisy market is likely to experience growth as healthcare providers seek effective treatments and management strategies for these interconnected conditions. ## Future Outlook The [Pleurisy Market](https://www.marketresearchfuture.com/reports/pleurisy-market-1711) is projected to grow at a 7.45% CAGR from 2025 to 2035, driven by advancements in diagnostic technologies and increasing healthcare expenditure. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in AI-driven diagnostic tools for early pleurisy detection - Expansion of specialized clinics focusing on pleurisy treatment options By 2035, the pleurisy market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Acute Pleurisy (Largest) vs. Recurrent Pleurisy (Fastest-Growing) In the US pleurisy market, acute pleurisy holds the largest share, driven by its prevalence and recognized symptoms that lead to prompt medical attention. Following this, chronic pleurisy is significant but trails in demand compared to its acute counterpart. Recurrent pleurisy, while smaller in current market share, is rapidly gaining traction as awareness and diagnosis improve, pushing it toward becoming a more dominant contender in the future. Growth trends indicate that acute pleurisy will continue to be the most diagnosed type due to its acute presentation and clear clinical guidelines. In contrast, recurrent pleurisy's growth is fueled by ongoing research and advancements in treatment options that enhance patient management. As healthcare professionals become more adept at recognizing and treating recurrent cases, this segment is expected to flourish, reflecting a broader trend towards comprehensive pleurisy treatment strategies. Acute Pleurisy (Dominant) vs. Recurrent Pleurisy (Emerging) Acute pleurisy is characterized by its sudden onset and strong correlation with underlying conditions such as infections or trauma, making it prevalent in acute care settings. This segment benefits from established treatment protocols, ensuring rapid intervention for patients. On the other hand, recurrent pleurisy represents an emerging opportunity as it is linked to chronic conditions that require long-term management. The rising incidence of recurring cases highlights the necessity for new therapeutic approaches and enhances the focus on patient education and continuous care, thereby positioning recurrent pleurisy as a critical area for growth within the US pleurisy market. ### By Diagnosis Method: Laboratory Tests (Largest) vs. Imaging Tests (Fastest-Growing) In the US pleurisy market, the diagnosis method segment showcases a diverse distribution of methodologies. Laboratory Tests hold the largest market share due to their essential role in confirming pleurisy and identifying underlying causes. Following closely are Imaging Tests, which have seen increased utilization owing to advancements in technology and their critical role in visualizing pleural effusions. Growth trends within the diagnosis method segment are being driven by technological advancements and increasing awareness among healthcare professionals. Imaging Tests are particularly emerging as the fastest-growing segment, benefiting from innovations that enhance diagnostic accuracy. The shift towards more efficient, less invasive testing methods is expected to further fuel this growth, making timely and accurate diagnosis a priority in the US pleurisy market. Laboratory Tests (Dominant) vs. Imaging Tests (Emerging) Laboratory Tests currently dominate the diagnosis method segment due to their comprehensive nature in analyzing biological samples, which is crucial for diagnosing pleurisy. These tests provide definitive results that help in determining the underlying causes of pleural conditions. On the other hand, Imaging Tests are gaining traction as an emerging method within the market. They utilize advanced imaging techniques to provide visual insight into pleural abnormalities. This segment is characterized by rapid technological developments, making Imaging Tests a vital tool for healthcare providers. The integration of new imaging technologies and techniques could potentially enhance the speed and accuracy of pleurisy diagnoses, positioning Imaging Tests as a key player in the future of diagnostic methodologies. ### By Treatment Type: Medication (Largest) vs. Surgical Procedures (Fastest-Growing) The treatment type segment in the US pleurisy market showcases a diverse array of options, with medication holding the majority market share. Medication proves to be the largest segment due to its widespread use in managing symptoms and improving patient quality of life without the need for invasive procedures. Surgical procedures, while having a smaller market share, are on a rapid growth trajectory as advancements in technology and techniques make them more accessible and appealing to physicians and patients alike. The growth trends in the treatment type segment are driven by an increasing prevalence of pleurisy and a growing understanding of effective treatment modalities. The rising interest in minimally invasive surgical procedures has stimulated innovation in the surgical segment, attracting patients who prefer less invasive options. Additionally, ongoing research is fostering the development of new medications, contributing to sustained growth and expansion across all treatment types. Medication: Dominant vs. Surgical Procedures: Emerging Medication remains the dominant treatment option in the US pleurisy market, largely due to its effectiveness in relieving symptoms such as pain and inflammation. Commonly prescribed medications include nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, offering reliable therapeutic outcomes. On the other hand, surgical procedures are gaining traction as an emerging alternative, particularly in cases where medication is inadequate for symptom relief. These procedures, including thoracentesis and pleurodesis, are becoming increasingly sophisticated, leading to safer and more effective interventions. As the market evolves, the shift towards integrating advanced surgical options alongside traditional medication highlights the dynamic nature of treatment preferences within the sector. ### By End User: Hospitals (Largest) vs. Home Care (Fastest-Growing) In the US pleurisy market, the distribution of market share among the end user segments reveals that hospitals currently hold the largest portion. Clinics also play a significant role, but their market share is relatively smaller compared to hospitals. Home care services, while currently a smaller segment, are fast gaining traction as a viable option for patients seeking comfort in their recovery environments. Growth trends indicate a shift towards home care in the US pleurisy market, driven by factors such as an aging population and increased preference for at-home healthcare solutions. Hospitals continue to dominate due to their comprehensive medical services, but the rapid adoption of home care models reflects evolving patient preferences. Enhanced technological advancements in remote monitoring are expected to further fuel the emergence of the home care segment. Hospitals: Dominant vs. Home Care: Emerging Hospitals are the dominant end user in the US pleurisy market, characterized by their ability to offer extensive resources and specialized care for patients with pleurisy. They are equipped with advanced diagnostic tools and treatment options, providing critical care that is essential for managing severe cases. In contrast, the home care segment is emerging as a preferred alternative, focusing on personalized care and comfort in a familiar setting. This segment is gaining momentum due to the increasing incidence of respiratory conditions and the desire for less invasive treatment methods. Home care allows for regular monitoring and support while facilitating quicker recovery times, catering primarily to patients who prefer to be treated in a home environment. ## Competitive Benchmarking The pleurisy market exhibits a competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Pfizer Inc (US), Bristol-Myers Squibb Company (US), and Roche Holding AG (CH) are actively shaping the market dynamics. Pfizer Inc (US) has positioned itself as a leader through its commitment to research and development, particularly in the realm of anti-inflammatory therapies, which are crucial for pleurisy treatment. Meanwhile, Bristol-Myers Squibb Company (US) emphasizes its robust pipeline of immunotherapies, aiming to leverage these advancements to enhance treatment outcomes for pleurisy patients. Roche Holding AG (CH) focuses on personalized medicine, utilizing its expertise in diagnostics to tailor treatments, thereby enhancing patient adherence and outcomes. Collectively, these strategies foster a competitive environment that prioritizes innovation and patient care.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach is particularly relevant in the pleurisy market, where timely access to medications is critical. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that influence pricing and availability. The collective influence of these major players shapes the competitive dynamics, as they engage in strategic collaborations and partnerships to enhance their market presence. In October Pfizer Inc (US) announced a collaboration with a leading biotechnology firm to develop a novel anti-inflammatory drug specifically targeting pleurisy. This strategic move is likely to bolster Pfizer's portfolio and enhance its competitive edge by addressing unmet medical needs in this area. The collaboration underscores the importance of innovation in driving market growth and improving patient outcomes. In September Bristol-Myers Squibb Company (US) launched a new clinical trial for its immunotherapy treatment aimed at patients with pleurisy. This initiative not only reflects the company's commitment to advancing treatment options but also positions it to capture a larger share of the market as it seeks to establish its therapies as the standard of care. The trial's outcomes could significantly influence treatment protocols and patient management strategies. In August Roche Holding AG (CH) expanded its diagnostic capabilities by integrating AI technologies into its testing processes for pleurisy-related conditions. This strategic enhancement is expected to improve diagnostic accuracy and speed, thereby facilitating timely treatment interventions. The integration of AI signifies a broader trend towards digitalization in healthcare, which is becoming increasingly vital in the competitive landscape. As of November the pleurisy market is witnessing trends that emphasize digitalization, sustainability, and the integration of advanced technologies such as AI. Strategic alliances are becoming more prevalent, as companies recognize the need to collaborate to enhance their offerings and improve patient care. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies approach market entry and product development, ultimately benefiting patients through improved treatment options. ## Recent News & Developments In recent months, the US Pleurisy Market has seen substantial developments, especially with companies like Bristol Myers Squibb, AstraZeneca, and Merck making strides in treatment advancements. The market has been impacted by increased investment in Research and Development (R&D) focused on pleural diseases, with Eli Lilly and Novartis actively expanding their portfolios. Notably, in October 2023, Merck announced promising trial results for a new drug aimed at pleurisy, raising anticipation among stakeholders. In terms of mergers and acquisitions, there has been heightened interest in strategic partnerships, although no significant transactions have been reported recently among the key companies, including Regeneron Pharmaceuticals and Pfizer. The growth of the market valuation for companies like Roche and AbbVie has been substantial over the past two years, driven by an improved understanding of pleural diseases and enhanced healthcare policies that effectively support patient care. Traditional therapies are also witnessing improvements, supporting major industry players as they adapt their strategies to market demands. Additionally, the commitment from the FDA to expedite approvals for new therapeutics has contributed to a more dynamic marketplace for pleurisy treatments in the US. ## Report Scope | MARKET SIZE 2024 | 137.2(USD Million) | | --- | --- | | MARKET SIZE 2025 | 147.42(USD Million) | | MARKET SIZE 2035 | 302.51(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.45% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer Inc (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Roche Holding AG (CH), AstraZeneca PLC (GB), Merck & Co., Inc. (US), Johnson & Johnson (US), Gilead Sciences, Inc. (US) | | Segments Covered | Type, Diagnosis Method, Treatment Type, End User | | Key Market Opportunities | Advancements in diagnostic technologies enhance early detection and treatment options in the pleurisy market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the pleurisy market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current market valuation of the US pleurisy market in 2024?** A: The market valuation of the US pleurisy market was $137.2 Million in 2024. **Q: What is the projected market size for the US pleurisy market by 2035?** A: The projected market size for the US pleurisy market is $302.51 Million by 2035. **Q: What is the expected CAGR for the US pleurisy market during the forecast period 2025 - 2035?** A: The expected CAGR for the US pleurisy market during the forecast period 2025 - 2035 is 7.45%. **Q: Which companies are the key players in the US pleurisy market?** A: Key players in the US pleurisy market include Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Roche Holding AG, AstraZeneca PLC, Merck & Co., Inc., Johnson & Johnson, and Gilead Sciences, Inc. **Q: What are the market segments for the US pleurisy market based on type?** A: The market segments based on type include Acute Pleurisy, Chronic Pleurisy, and Recurrent Pleurisy, with valuations ranging from $40.0 Million to $110.0 Million. **Q: What are the primary diagnosis methods used in the US pleurisy market?** A: Primary diagnosis methods in the US pleurisy market include Physical Examination, Imaging Tests, and Laboratory Tests, with Imaging Tests valued at $130.0 Million. **Q: What treatment types are available in the US pleurisy market?** A: Treatment types in the US pleurisy market include Medication, Surgical Procedures, and Therapeutic Procedures, with Surgical Procedures valued at $110.0 Million. **Q: Which end users are significant in the US pleurisy market?** A: Significant end users in the US pleurisy market include Hospitals, Clinics, and Home Care, with Hospitals valued at $135.0 Million. **Q: How does the market valuation for Chronic Pleurisy compare to Acute Pleurisy?** A: The market valuation for Chronic Pleurisy ranges from $50.0 Million to $110.0 Million, which is higher than the valuation for Acute Pleurisy, ranging from $40.0 Million to $90.0 Million. **Q: What does the future hold for the US pleurisy market in terms of growth?** A: The future of the US pleurisy market appears promising, with a projected growth to $302.51 Million by 2035, indicating robust demand and development. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-pleurisy-market-20015*